A detailed history of Pdt Partners, LLC transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Pdt Partners, LLC holds 319,715 shares of ARQT stock, worth $3.01 Million. This represents 0.29% of its overall portfolio holdings.

Number of Shares
319,715
Previous 319,715 -0.0%
Holding current value
$3.01 Million
Previous $2.97 Million -0.0%
% of portfolio
0.29%
Previous 0.3%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 15, 2024

SELL
$7.24 - $12.53 $3,699 - $6,402
-511 Reduced 0.16%
319,715 $2.97 Million
Q1 2024

May 15, 2024

BUY
$3.25 - $11.77 $1.04 Million - $3.77 Million
320,226 New
320,226 $3.17 Million
Q3 2023

Nov 14, 2023

BUY
$5.31 - $10.98 $395,610 - $818,042
74,503 Added 61.79%
195,081 $1.04 Million
Q2 2023

Aug 14, 2023

SELL
$7.51 - $15.0 $262,144 - $523,590
-34,906 Reduced 22.45%
120,578 $1.15 Million
Q1 2023

May 15, 2023

BUY
$10.23 - $17.14 $998,519 - $1.67 Million
97,607 Added 168.65%
155,484 $1.71 Million
Q4 2022

Feb 14, 2023

BUY
$13.96 - $20.4 $631,047 - $922,161
45,204 Added 356.7%
57,877 $856,000
Q3 2022

Nov 14, 2022

BUY
$17.85 - $26.95 $226,213 - $341,537
12,673 New
12,673 $242,000

Others Institutions Holding ARQT

About Arcutis Biotherapeutics, Inc.


  • Ticker ARQT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,187,500
  • Market Cap $568M
  • Description
  • Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...
More about ARQT
Track This Portfolio

Track Pdt Partners, LLC Portfolio

Follow Pdt Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.